The Alexandria Real Estate Equities-backed regenerative medicine developer floated at the bottom of its range while cutting the number of shares.

Frequency Therapeutics, a US-based degenerative disease drug developer backed by life sciences real estate investment trust Alexandria Real Estate Equities, went public today in an $84m initial public offering. The company floated at the foot of the $14 to $16 range it set last month, while reducing the number of shares in the IPO from…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.